MDT

86.5

0%↓

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

MDT

86.5

0%↓

115.03

-0.36%↓

VEEV

173.24

-0.36%↓

HQY

83.75

-1%↓

PHR.US

8.92

+6.95%↑

Home・Aandelen Lijst・Lisata Therapeutics

L
Lisata Therapeutics

Open

4.99 -0.4

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.99

Max

5.01

Belangrijke statistieken
By Trading Economics
Inkomsten	1.3M -3M
Verkoop	100K 100K
Winstmarge	-2,954
Werknemers	21

Dividenden
By Dow Jones
Volgende Winsten	7 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	531K 40M
Vorige openingsprijs	5.39
Vorige sluitingsprijs	4.99

Lisata Therapeutics Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

3 apr 2026, 04:27 UTC

Belangrijke Nieuwsgebeurtenissen

Singapore PM Warns That Fallout From Mideast War Could Outlast Conflict

5 apr 2026, 23:55 UTC

Marktinformatie

Gold Falls Amid Dollar Strength, Inflation Worries -- Market Talk

5 apr 2026, 23:45 UTC

Marktinformatie

Nikkei May Decline on Concerns About Energy Costs -- Market Talk

5 apr 2026, 23:42 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

5 apr 2026, 23:42 UTC

Marktinformatie

China's Consumer Inflation Likely Eased in March -- Market Talk

5 apr 2026, 23:38 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Futures Rise Amid Increased Supply Disruption Concerns -- Market Talk

5 apr 2026, 12:57 UTC

Belangrijke Nieuwsgebeurtenissen

Some Italian Airports Report Jet-Fuel Shortages -- WSJ

3 apr 2026, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 18:30 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $30 Million Jet. -- Barrons.com

3 apr 2026, 18:14 UTC

Marktinformatie

Eli Lilly Seen as Possible GLP-1 Leader With New Pill Approval -- Market Talk

3 apr 2026, 17:50 UTC

Marktinformatie

Microsoft's AI Development Will Weigh on Near-Term Azure Growth -- Market Talk

3 apr 2026, 17:44 UTC

Acquisities, Fusies, Overnames

SBA Stock Just Had a Big Day. Why It's Suddenly Hot. -- Barrons.com

3 apr 2026, 16:50 UTC

Belangrijke Nieuwsgebeurtenissen

An F15-E Just Went Down in Iran. What to Know About the $90 Million Jet. -- Barrons.com

3 apr 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 16:12 UTC

Winsten

Oil Stocks Look Tapped Out. Why It's Time to Move Into Other Sectors. -- Barrons.com

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Crypto Markets May Be Active Over Holiday Weekend -- Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Equities Roundup: Market Talk

3 apr 2026, 15:56 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Global Forex and Fixed Income Roundup: Market Talk

3 apr 2026, 15:20 UTC

Belangrijke Nieuwsgebeurtenissen

Berkshire, Travelers Join U.S. Plan to Insure Shippers in the Hormuz Strait -- Barrons.com

3 apr 2026, 15:08 UTC

Acquisities, Fusies, Overnames

OpenAI Makes Surprise Media Acquisition Ahead of IPO. Why It Will Fail. -- Barrons.com

3 apr 2026, 14:11 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Oil Shock From War in Iran May Show Up In 2Q Job Growth Data -- Market Talk

3 apr 2026, 12:56 UTC

Marktinformatie

Treasury Yields, Dollar Higher Following Robust March Hiring -- Market Talk

3 apr 2026, 08:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 08:01 UTC

Marktinformatie

Meituan's Profitability Likely to Improve This Year -- Market Talk

3 apr 2026, 07:45 UTC

Marktinformatie

LG Electronics Could Post Above-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Naver Likely to Post Below-Consensus 1Q Earnings -- Market Talk

3 apr 2026, 06:17 UTC

Marktinformatie

Global Equities Roundup: Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

China Merchants Port Earnings Likely to Recover This Year -- Market Talk

3 apr 2026, 04:33 UTC

Marktinformatie

Global Equities Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Lisata Therapeutics Prognose

Beoordelingsconsensus

By TipRanks

Neutraal

1 ratings

Buy

Hold

Sell

Gebaseerd op 1 analisten die aandelenratings hebben gegeven aan Lisata Therapeutics - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Winst voor belastingen

Verkoop

Operationele winst

Over Lisata Therapeutics

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.